45 research outputs found
European Guidelines for Obesity Management in Adults
Obesity is a chronic metabolic disease characterised by an increase of body fat stores. It is a gateway to ill health, and it has become one of the leading causes of disability and death, affecting not only adults but also children and adolescents worldwide. In clinical practice, the body fatness is estimated by BMI, and the accumulation of intra-abdominal fat (marker for higher metabolic and cardiovascular disease risk) can be assessed by waist circumference. Complex interactions between biological, behavioural, social and environmental factors are involved in regulation of energy balance and fat stores. A comprehensive history, physical examination and laboratory assessment relevant to the patient's obesity should be obtained. Appropriate goals of weight management emphasise realistic weight loss to achieve a reduction in health risks and should include promotion of weight loss, maintenance and prevention of weight regain. Management of co-morbidities and improving quality of life of obese patients are also included in treatment aims. Balanced hypocaloric diets result in clinically meaningful weight loss regardless of which macronutrients they emphasise. Aerobic training is the optimal mode of exercise for reducing fat mass while a programme including resistance training is needed for increasing lean mass in middle-aged and overweight/obese individuals. Cognitive behavioural therapy directly addresses behaviours that require change for successful weight loss and weight loss maintenance. Pharmacotherapy can help patients to maintain compliance and ameliorate obesity-related health risks. Surgery is the most effective treatment for morbid obesity in terms of long-term weight loss. A comprehensive obesity management can only be accomplished by a multidisciplinary obesity management team. We conclude that physicians have a responsibility to recognise obesity as a disease and help obese patients with appropriate prevention and treatment. Treatment should be based on good clinical care, and evidence-based interventions; should focus on realistic goals and lifelong multidisciplinary management. (C) 2015 S. Karger GmbH, Freibur
Effects of a hops (Humulus lupulus L.) dry extract supplement on self-reported depression, anxiety and stress levels in apparently healthy young adults:a randomized, placebo-controlled, double-blind, crossover pilot study
OBJECTIVE: The Humulus lupulus L. plant (hops) is used as a herbal medicinal product for anxiety/mood disorders. Our aim was to study the effects of a hops dry extract on self-reported depression, anxiety and stress levels in young adults. DESIGN: Apparently healthy young adults from our university completed the Depression Anxiety Stress Scale-21 (DASS-21) and those reporting at least mild depression, anxiety and stress were invited to complete the study intervention. This followed a randomized (1:1), placebo-controlled, double-blind, crossover design with two 4-week intervention periods (hops or placebo; two 0.2 gr capsules once daily) separated by a 2-week wash-out. Anthropometric measurements, DASS-21 assessments and measurements of morning cortisol plasma levels were performed at the beginning and the end of the 4-week treatment periods. RESULTS: 36 participants (Females/Males: 31/5; age: 24.7±0.5 years) completed the study intervention (attrition: 6/42). No significant changes in body weight and composition or morning circulating cortisol were noted with the hops or placebo. Significantly decreased DASS-21 anxiety, depression and stress scores were documented with hops (9.2±7.3 vs. 5.1±5.9, 11.9±7.9 vs. 9.2±7.4, and 19.1±8.1 vs. 11.6±8.1; all p values <0.05), which were significantly greater compared to those caused by the placebo (all p values <0.05). CONCLUSION: In otherwise healthy young adults reporting at least mild depression, anxiety and stress symptoms, daily supplementation with a hops dry extract can significantly improve all these symptoms over a 4-week period. These beneficial effects agree with the indication of hops for anxiety/mood disorders and restlessness, as approved by the German Commission E
Lipid accumulation product in relation to 10-year cardiovascular disease incidence in Caucasian adults: The ATTICA study
Background and aims The lipid accumulation product (LAP) is an index describing lipid over-accumulation based on waist circumference (WC) and fasting triglycerides, and can outperform the body mass index (BMI) in recognizing cardiovascular disease (CVD) risk. We aimed to explore the association of LAP with long-term CVD risk and compare its CVD-predictive value against common anthropometric indices/ratios of obesity. Methods ATTICA is a prospective, population-based cohort that recruited 3042 adults without pre-existing CVD from the Greek general population (age 18–89 years; 1514 men). The 10-year study follow-up (2011–2012) captured the fatal/non-fatal CVD incidence in 2020 participants (50% men). Baseline LAP (cm⋅mmol/L) was calculated and analyzed in relation to the 10-year CVD incidence. Results In total, 317 CVD cases (15.7%) were documented during the follow-up. Baseline LAP showed a significant positive association with the 10-year CVD incidence, even after adjusting for hypertension, diabetes, hypercholesterolemia, smoking, physical activity, Mediterranean diet adherence, and key pro-inflammatory biomarkers (Hazard Ratios per 10 cm mmol/L of LAP ranging from 1.1 to 1.21, p = 0.04). Moreover, LAP predicted the 10-year CVD study incidence better than common obesity indices (BMI, WC, waist-to-hip, waist-to-height ratio). Conclusions These findings support and independent positive association between LAP and long-term CVD incidence in CVD-free Caucasian adults from the general population
Peripheral Mononuclear Cell Resistin mRNA Expression Is Increased in Type 2 Diabetic Women
Resistin has been shown to cause insulin resistance and to impair glucose tolerance in rodents, but in humans its physiological role still remains elusive. The aim of this study was to examine whether resistin mRNA expression in human peripheral mononuclear cells (PBMCs) and its corresponding plasma levels are altered in type 2 diabetes. Resistin mRNA levels were easily detectable in human PBMC, and found to be higher in DM2 compared to healthy women (P = .05). Similarly, mononuclear mRNA levels of the proinflammatory cytokines IL-1β, TNF-α, and IL-6 were all significantly higher in DM2 compared to control women (P < .001). The corresponding plasma resistin levels were slightly, but not significantly, increased in DM2 women (P = .051), and overall, they correlated significantly with BMI (r = 0.406, P = .010) and waist circumference (r = 0.516, P = .003), but not with fasting insulin levels or HOMA-IR. Resistin mRNA expression is increased in PBMC from DM2 women, together with increased expression of the inflammatory cytokines IL-1β, TNF-α, and IL-6, independent of obesity. These results suggest that resistin and cytokines might contribute to the low-grade inflammation and the increased atherogenic risk observed in these patients
Olive oil consumption and 10-year (2002–2012) cardiovascular disease incidence: the ATTICA study
Olive oil, being rich in mono-unsaturated fatty acids and anti-inflammatory compounds, may have protective effects against cardiovascular disease (CVD). The aim of the present work was to examine the association of olive oil consumption with the 10-year CVD incidence in adults without pre-existing CVD. After controlling for various covariates, an inverse association between exclusive olive oil use and the risk of developing CVD was observed (relative risk 0.07, 95% CI: 0.01-0.66) compared to those not consuming olive oil. Further adjustment for fibrinogen plasma levels (among various inflammatory markers) showed a significant mediation effect on the previous association. These findings support exclusive olive oil consumption, a key component of the Mediterranean diet, for the primary CVD prevention, in adults without pre-existing disease. Circulating fibrinogen levels appear to play a mediating role in this relationship
Association of depression and anxiety status with 10-year cardiovascular disease incidence among apparently healthy Greek adults:the ATTICA study
Background: Chronic stress frequently manifests with anxiety and/or depressive symptomatology and may have detrimental cardiometabolic effects over time. As such, recognising the potential links between stress-related psychological disorders and cardiovascular disease (CVD) is becoming increasingly important in cardiovascular epidemiology research. The primary aim of this study was to explore prospectively potential associations between clinically relevant depressive symptomatology and anxiety levels and the 10-year CVD incidence among apparently healthy Greek adults. Design: A population-based, health and nutrition prospective survey. Methods: In the context of the ATTICA Study (2002–2012), 853 adult participants without previous CVD history (453 men (45 ± 13 years) and 400 women (44 ± 18 years)) underwent psychological evaluations through validated, self-reporting depression and anxiety questionnaires. Results: After adjustment for multiple established CVD risk factors, both reported depression and anxiety levels were positively and independently associated with the 10-year CVD incidence, with depression markedly increasing the CVD risk by approximately fourfold (adjusted odds ratio (95% confidence interval) 3.6 (1.3, 11) for depression status; 1.03 (1.0, 1.1) for anxiety levels). Conclusions: Our findings indicate that standardised psychological assessments focusing on depression and anxiety should be considered as an additional and distinct aspect in the context of CVD preventive strategies that are designed and implemented by health authorities at the general population level
Interdisciplinary European guidelines on surgery of severe obesity
W 2005 roku, dzięki wspólnemu wysiłkowi głównych europejskich
towarzystw naukowych aktywnych na polu leczenia otyłości został
powołany zespół ekspertów nazwany Bariatryczno-Naukową
Grupą Badawczą (BSCG). Towarzystwami, które stworzyły ten
zespół i oddelegowały swoich przedstawicieli do prac w opracowaniu
wytycznych były: Międzynarodowe Towarzystwo Chirurgicznego
Leczenia Otyłości (IFSO), Oddział Europejski Międzynarodowego
Towarzystwa Chirurgicznego Leczenia Otyłości
(IFSO-EC), Europejskie Towarzystwo Badań nad Otyłością
(EASO), Europejska Grupa ds. Otyłości u Dzieci (ECOG) (razem
z Międzynarodową Grupą Zwalczania Otyłości). Bariatryczno-Naukowa
Grupa Badawcza składała się z władz reprezentujących
powyższe towarzystwa (czterech czynnych przewodniczących,
dwóch byłych, jeden honorowy, dwóch dyrektorów wykonawczych),
a także najwybitniejszych ekspertów w tej dziedzinie. Skład BSCG pozwolił na całościowe objęcie zagadnienia leczenia
otyłości olbrzymiej z uwzględnieniem różnorodności geograficznej
i etnicznej Europy. Członkowie BSCG odbyli wiele spotkań
poświęconych stworzeniu wytycznych, które odzwierciedlałyby
współczesną wiedzę i doświadczenie w zakresie leczenia
otyłości olbrzymiej.In 2005, for the first time in European history, an extraordinary expert
panel named BSCG (Bariatric Scientific Collaborative Group),
was appointed through joint effort of the major European scientific
societies which are active in the field of obesity management. Societies
that constituted this panel were: IFSO - International Federation
for the Surgery of Obesity, IFSO-EC - International Federation
for the Surgery of Obesity - European Chapter, EASO - European Association for Study of Obesity, ECOG - European
Childhood Obesity Group, together with the IOTF (International
Obesity Task Force) which was represented during the completion
process by its representative. The BSCG was composed not
only of the top officers representing the respective scientific societies
(four acting presidents, two past presidents, one honorary president,
two executive directors), but was balanced with the presence
of many other key opinion leaders in the field of obesity. The
BSCG composition allowed the coverage of key disciplines in comprehensive
obesity management, as well as reflecting European
geographical and ethnic diversity. This joint BSCG expert panel
convened several meetings which were entirely focused on guidelines
creation, during the past 2 years. There was a specific effort
to develop clinical guidelines, which will reflect current knowledge,
expertise and evidence based data on morbid obesity treatment
Management of obesity in adults: European clinical practice guidelines
Stworzenie jednolitych wytycznych postępowania w otyłości jest
złożone. Obejmują one zarówno zalecenia diagnostyczne, lecznicze,
jak i działania w zakresie prewencji. Wobec wielu publikacji
i różnic poglądów oraz świadomości krótkotrwałości efektu odchudzającego
u poszczególnych osób wielu uważa, że trudno jest
ustalić właściwe postępowanie w otyłości. Różnorodność zasad
postępowania w kraju oraz pomiędzy regionami Europy utrudnia
ustalenie i wprowadzenie standardów. W ustalaniu obecnych wytycznych
za podstawę brano wiedzę opartą na dowodach (EBM), a w razie wątpliwości uzupełniano na podstawie doświadczenia
klinicznego i różnorodności regionalnej oraz uzgodnionego stanowiska
zespołu.
W podsumowaniu stwierdzono, że: 1) lekarz jest odpowiedzialny
za rozpoznanie otyłości jako choroby oraz pomoc w odpowiedniej
prewencji i leczeniu; 2) leczenie powinno być oparte na dobrej
praktyce klinicznej i EBM; 3) leczenie otyłości powinno wyznaczać
indywidualne realne cele i dożywotnie postępowanie.The development of consensus guidelines for obesity is complex. It
involves recommending both treatment interventions and interventions
related to screening and prevention. With so many publications
and claims, and with the awareness that success for the individual
is short-lived, many find it difficult to know what action is appropriate
in the management of obesity. Furthermore, the significant
variation in existing service provision both within countries as well
as across the regions of Europe makes a standardised approach,
even if evidence-based, difficult to implement. In formulating these
guidelines, we have attempted to use an evidence based approach
while allowing flexibility for the practicing clinician in domains where
evidence is currently lacking and ensuring that in treatment there
is recognition of clinical judgment and of regional diversity as well
as the necessity of an agreed approach by the individual and family.
We conclude that 1) physicians have a responsibility to recognise
obesity as a disease and help obese patients with appropriate
prevention and treatment, 2) treatment should be based on good
clinical care and evidence- based interventions and 3) obesity treatment
should focus on realistic goals and lifelong management
Modeling anthropometric indices in relation to 10-year (2002-2012) incidence of cardiovascular disease, among apparently healthy individuals:the ATTICA study
Aims: Body fat accumulation is implicated in the development of cardiovascular disease (CVD). Our objective was to explore potential associations between anthropometric indices and the 10-year CVD incidence in Greek adults without previous CVD. Methods: During 2001–2, we enrolled 3042 adults without CVD from the general population of Attica, Greece. In 2011–2, the 10-year study follow-up was performed, recording the CVD incidence in 1958 participants with baseline body mass index (BMI) ≥18.5 kg/m2. Results: The study 10-year CVD incidence was 15.8%, exhibiting a gradual increase according to the baseline body mass index (BMI) category. Baseline BMI ≥30 kg/m2 was related with significantly higher 10-year CVD risk compared to BMI <25 kg/m2, even after adjustment for age and other known CVD risk factors. Baseline BMI, waist circumference, waist-to-hip ratio, waist-to-height ratio and waist-to-hip-to-height ratio were independently associated with the 10-year CVD risk in multi-adjusted models. Gender-specific analyses showed that these associations were more evident in men compared to women, with baseline BMI exhibiting an independent association with the 10-year CVD incidence in men. Conclusions: Our results indicate that even simple anthropometric indices exhibit independent associations with CVD risk in a representative sample of the Greek general population without previous CVD